These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 7629249

  • 1. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ, Nam SY, Kim KR, Lee HC, Cho JH, Nam MS, Song YD, Lim SK, Huh KB.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [Abstract] [Full Text] [Related]

  • 2. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
    Nam SY, Lee, Kim KR, Lee HC, Nam MS, Cho JH, Huh KB.
    Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
    [Abstract] [Full Text] [Related]

  • 3. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [Abstract] [Full Text] [Related]

  • 4. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R, Cordido F, Peñalva A, Alvarez CV, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [Abstract] [Full Text] [Related]

  • 5. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [Abstract] [Full Text] [Related]

  • 6. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [Abstract] [Full Text] [Related]

  • 7. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
    Maccario M, Procopio M, Grottoli S, Oleandri SE, Boffano GM, Taliano M, Camanni F, Ghigo E.
    Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
    [Abstract] [Full Text] [Related]

  • 8. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 9. Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism.
    Lee EJ, Kim KR, Lee HC, Cho JH, Nam MS, Nam SY, Song YD, Lim SK, Huh KB.
    Metabolism; 1995 Nov; 44(11):1509-12. PubMed ID: 7476342
    [Abstract] [Full Text] [Related]

  • 10. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
    Lanzi R, Luzi L, Caumo A, Andreotti AC, Manzoni MF, Malighetti ME, Sereni LP, Pontiroli AE.
    Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
    [Abstract] [Full Text] [Related]

  • 11. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
    Leal-Cerro A, Jimenez LM, Astorga R, Fernandez-Lopez I, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
    [Abstract] [Full Text] [Related]

  • 12. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
    Alvarez P, Isidro L, Peinó R, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
    [Abstract] [Full Text] [Related]

  • 13. Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
    Lanzi R, Manzoni MF, Andreotti AC, Malighetti ME, Bianchi E, Sereni LP, Caumo A, Luzi L, Pontiroli AE.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2239-43. PubMed ID: 9215300
    [Abstract] [Full Text] [Related]

  • 14. Influence of pyridostigmine on growth hormone (GH) response to GH-releasing hormone pre- and postprandially in normal and obese subjects.
    De Marinis L, Mancini A, Zuppi P, Calabrò F, Fiumara C, Lagonigro G, Fabrizi ML, Sammartano L.
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1253-7. PubMed ID: 1592867
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.
    Pontiroli AE, Lanzi R, Monti LD, Sandoli E, Pozza G.
    J Clin Endocrinol Metab; 1991 Feb; 72(2):492-5. PubMed ID: 1671389
    [Abstract] [Full Text] [Related]

  • 16. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary.
    Casanueva FF, Villanueva L, Dieguez C, Diaz Y, Cabranes JA, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A.
    J Clin Endocrinol Metab; 1987 Oct; 65(4):634-42. PubMed ID: 2888782
    [Abstract] [Full Text] [Related]

  • 17. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
    Pontiroli AE, Lanzi R, Monti LD, Pozza G.
    J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
    [Abstract] [Full Text] [Related]

  • 18. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P, Isidro ML, Garcia-Buela J, Leal-Cerro A, Broglio F, Tassone F, Ghigo E, Dieguez C, Casanueva FF, Cordido F.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [Abstract] [Full Text] [Related]

  • 19. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
    Cordido F, Peñalva A, Peino R, Casanueva FF, Dieguez C.
    Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
    [Abstract] [Full Text] [Related]

  • 20. The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
    Scacchi M, Orsini F, Cattaneo A, Grasso A, Filippini B, Pecori Giraldi F, Fatti LM, Moro M, Cavagnini F.
    Eur J Endocrinol; 2010 Aug; 163(2):201-6. PubMed ID: 20460421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.